UNSPSC 51342501: Abacavir

This classification denotes a reverse transcriptase inhibitor with the molecular formula C14H18N6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WR2TIP26VS, chemically known as 2-cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-, (1s-cis)- but generally known as abacavir, which bears US NIH Compound Identifier 65140. Abacavir most often appears in forms succinate and sulfate, and is sometimes combined with lamivudine and zidovudine.

UNSPSC 51342501 Abacavir, a Commodity code, maps to pharmaceutical supply contracts, though recent state and local opportunities show minimal activity tagged directly under this code. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through MMCAP Infuse to Chartwell Rx LLC in August 2026 for antibiotic pharmaceuticals (Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg), totaling $2,999,999.11 over 12 months with two one-year renewal options. A second opportunity from Seminole County, Florida, posted in June 2026 sought 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through an Invitation for Bid. These examples illustrate that state and local governments procure pharmaceutical products and related health supplies through cooperative purchasing consortia and direct competitive bids, with contracts structured around annual volumes, quarterly or regular deliveries, and multi-year terms with renewal options.

The issuing bodies are primarily state health departments and county health authorities. Geographic activity appears concentrated in the Southeast and Midwest, with Illinois and Florida represented in recent awards. The Abacavir code itself shows limited recent posting activity; the opportunities identified under this code do not actually source Abacavir directly but rather related pharmaceuticals and health supplies, suggesting either sparse procurement volume in this specific drug category or tagging inconsistency in the source data. Firms pursuing pharmaceutical supply contracts with state and local health agencies should monitor cooperative purchasing vehicles such as MMCAP Infuse, track IFB and RFP activity from state departments of public health and county health authorities, and prepare for delivery and logistics requirements built into proposal scoring.